Cannovum Cannabis AG Logo

Cannovum Cannabis AG

Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.

27N0 | DU

Overview

Corporate Details

ISIN(s):
DE000A30VHF2 (+2 more)
LEI:
894500IT61F9P85YMM31
Country:
Germany
Address:
Stresemannstraße 23, 10963 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cannovum Cannabis AG is a pharmaceutical company that operates as an importer, wholesaler, and manufacturer of medical cannabis products. The company focuses on providing patients with cannabis-based therapies, supported by medical-scientific education and distribution services. As one of the first fully licensed cannabis companies to be publicly listed in Germany, Cannovum is leveraging its market position to expand into the emerging recreational cannabis sector. This strategic expansion includes providing cultivation areas and infrastructure for cannabis social clubs to address the adult-use consumer market following recent legalization.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-02-27 21:05
Delisting Announcement
Cannovum Cannabis AG: Liquidation and sale of investments in the cannabis sector
English 5.8 KB
2025-02-26 21:05
Delisting Announcement
Cannovum Cannabis AG: Liquidation and sale of investments in the cannabis sector
English 5.8 KB
2024-08-01 07:36
Regulatory News Service
Cannovum Cannabis AG: Far-reaching partnership with H.i. Greeny+ GmbH and H.i C…
English 9.4 KB
2024-06-26 09:34
Regulatory News Service
Cannovum Cannabis AG: 'Cannabis for Germany', sale of fake hemp in 1,000 Aldi S…
English 9.0 KB
2024-06-07 07:00
Legal Proceedings Report
Cannovum Cannabis AG: Bundestag confirms Cannovum Cannabis AG's business model …
English 7.6 KB
2024-06-04 10:20
Share Issue/Capital Change
Cannovum Cannabis AG: Cash capital increase from authorized capital with subscr…
English 5.9 KB
2024-03-22 11:45
Regulatory News Service
Cannovum Cannabis AG: Federal Council confirms cannabis legalization as of Apri…
English 9.5 KB
2024-03-05 09:30
Regulatory News Service
Cannovum Cannabis AG: Areas for more than 500 cannabis clubs are available in t…
English 9.0 KB
2024-03-05 06:59
Regulatory News Service
Cannovum Cannabis AG: Areas for more than 500 cannabis clubs are available in t…
English 9.1 KB
2024-02-23 15:51
Regulatory News Service
Cannovum Cannabis AG: Bundestag approves legalization of cannabis in Germany, h…
English 8.1 KB
2024-02-02 09:37
Earnings Release
Cannovum Cannabis AG: April 2024 starts the legalization of cannabis in Germany…
English 7.8 KB
2023-11-14 15:55
Board/Management Information
Cannovum Cannabis AG: High-profile business leaders from advertising and retail…
English 7.3 KB
2023-11-06 13:39
Regulatory News Service
Cannovum Cannabis AG: Legalization of cannabis is imminent, new premium partner…
English 10.6 KB
2023-08-07 07:30
Regulatory News Service
Cannovum Cannabis AG: Exclusive partnership and million-dollar sales potential …
English 9.2 KB
2023-07-17 10:47
Regulatory News Service
Cannovum Cannabis AG: New partner strengthens offer for private cultivation of …
English 10.4 KB

Automate Your Workflow. Get a real-time feed of all Cannovum Cannabis AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cannovum Cannabis AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cannovum Cannabis AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.